Biography
Dr Xiang-Qun (Sean) Xie is an Associate Dean for Research Innovation at School of Pharmacy and a Professor of Pharmaceutical Sciences/Drug Discovery Institute, and a PI of an integrated Medicinal Chemistry Biology laboratory of CompuGroup, BioGroup and ChemGroup (www.CBLigand.org/XieLab) at University of Pittsburgh. He is a charter member of the Science Advisory Board to the US FDA. He is a Founding Director of Computational Chemical Genomics Screening Center (www.CBLigand.org/CCGS), and a Director/PI of NIH National Center of Excellence for CDAR (www.CDARCenter.org). He holds joint positions at Dept of Computational Biology and Dept of Structural Biology, and Pitt Cancer Institute MT/DD Program. He is an Editorial Advisory Board member for AAPS Journal and American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology Toxicology. He was a Charter Member of NIH BPNS Study Section, and an ad hoc expert reviewer for UK MRC foundation; the Wellcome Trust Fund; the Netherland Organization for Scientific Research Council; the Austrian Science Fund (FWF) Erwin Schrödinger Fellowship; and the Chinese Natural Science Foundation. He holds/held honorary professorship in top institutes and colleges of pharmacy in China, including Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Stem Cell Medical Center; Zhejing University, Fudan University, Shanghai Jiaotong University and Sun Yat-Sen Univesity and Kunming Institute of Botany, Chinese Academy of Sciences. He was an invited International Assessment Panelist for Fudan University, a member of the Board of Directors of the Chinese Association of Professionals in Science and Technology, and a Chair of the CAPST-Biomedical & Pharmaceutical Society. Prof Xie and his team are known for their pioneering research for the development of internationally recognized diseases domain-specific chemogenomics knowledgebases, which is an integrated platform of “Big Data to Knowledge†computational chemogenomics-based target identification and system pharmacology for translational research. His recent work on Alzheimer’s disease specific chemogenomics database (www.CBLigand.org/AD/) was on 2014 coverpage story of a top peer-reviewed ACS journal. The innovation work includes GPU-accelerated cloud computing TargetHunter program for drug target identification (www.CBLigand.org/TargetHunter) (2013 AAPS special theme issue). His lab was the first discovered/patented INK4C-targeting small molecule inhibitors for hematopoietic stem cell expansion (Nature Comm 2015), was the first discovered/patented p62ZZ chemical inhibitors for multiple myeloma (Nature Leukemia 2015), and also reported/patented novel ligands specific to cannabinoid CB2 receptor for osteoporosis and cancers. His invention discovery patents have been successfully licensed out to Biotech/Pharma. Overall, his developed integrated cloud computing knowledgebases help to bridge the knowledge gap between biology and chemistry, and to facilitate target identification, drug repurposing, and system pharmacology analyses in a chemogenomics scale for precision medicine drug discovery. As a result, he is a recipient of 2014 AAPS Award for Outstanding Research Achievements. Dr Xie received MD in Pharmacy from the Second Military Medical University in Shanghai China, PhD in Medicinal Chemistry from the School of Pharmacy, University of Connecticut, and Executive MBA degree, and the Shared Leadership Cohort Development Experience Workshop Training by JPorcari & Associates.
Research Interest
Biography
Hawa ZE Jaafar completed her PhD in 1995 from Nottingham University, United Kingdom in the area of Plant Environmental Physiology. She is very active both in environmental manipulation of herbal secondary metabolism research, and in community development of herbal materials and products. Currently, she is the Director of the University Community Transformation Centre (UCTC) UPM, and a member of the National Herbal Implementation Committee. She has published about 150 papers mostly in high impact journals, more than150 other articles in bulletin, monographs, books and chapters, and presented more than 130 papers nationally and abroad. She is very active in professional activities as a President, Vice President, Chief Editor and Editorial Member. She is also very involved in the development of Roadmap of the National Herbal Industry in Malaysia in 2010. She established the Controlled Environment System in Malaysia in 1991, and had assisted Sana’a University Yemen to establish the Protected Agriculture Centre (2006-2010).
Research Interest
Environmental manipulation of herbal secondary metabolism research and Community development of herbal materials and products
Biography
Zhou is presently a Professor, Associate Vice President of Global Medical Development, Associate Dean of International Research, and Chair of the Department of Pharmaceutical Sciences, College of Pharmacy & Morsani College of Medicine, University of South Florida, Tampa, Florida 33612. Professor Zhou completed his clinical medical training in China in 1989 and obtained his PhD in 2001 from the Faculty of Medicine and Health Sciences, the University of Auckland, Auckland, New Zealand. He continued his postdoctoral training at the University of Auckland until November 2002. Since 2002, Dr Zhou has served as a faculty member for the National University of Singapore, Queensland University of Technology (Australia), RMIT University (Australia), and now University of South Florida. Dr Zhou’s major research interests are drug discovery/systems pharmacology, drug metabolism/drug transport & pharmacokinetics, pharmacogenomics/pharmacogenetics, nanomedicine and Chinese medicine. Professor Zhou has published more than 330 peer-reviewed papers in various pharmacology and medical journals including New England Journal of Medicine, Cancer Research, Journal of Biological Chemistry, Clinical Pharmacology and Therapeutics, Carcinogenesis, JPET, Drug Metabolism & Disposition, and Clinical Cancer Research. He has also published 16 books and book chapters and more than 310 conference abstracts. His work has been cited more than 8,600 times by other colleagues with a H-index of 46. He has received more than US$22.0 million grants from various funding bodies and industries. To date, he has trained 24 PhD students, 12 MSc/Honors students, 14 postdoctoral fellows and 25 visiting faculty. Dr Zhou serves as an editor-in-chief or editor for 16 journals including Drug, Healthcare and Patient Safety, Drug Metabolism Letters, and Current Drug Metabolism and is the editorial board member of more than 50 medical and pharmacological journals. Dr Zhou has given more than 100 invited seminars/keynote presentations to a variety of academic institutes, government agencies, and high-profile international conferences. He is a recipient of several teaching and research awards, a member of numerous national and international professional societies, and a visiting professor of many reputable research universities.
Research Interest